Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels

Alpo Vuorio; Petri T Kovanen; Frederick Raal

doi:10.21037/atm-25-40

Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels

Ann Transl Med. 2025 Apr 30;13(2):11. doi: 10.21037/atm-25-40. Epub 2025 Apr 29.

Authors

Alpo Vuorio^{1

2}, Petri T Kovanen³, Frederick Raal⁴

Affiliations

¹ Mehiläinen Airport Health Centre, Vantaa, Finland.
² Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
³ Wihuri Research Institute, Helsinki, Finland.
⁴ Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

No abstract available

Keywords: Lipoprotein(a) [Lp(a)]; atherosclerotic cardiovascular disease (ASCVD); low-density lipoprotein cholesterol (LDL-C); muvalaplin; small molecule Lp(a) inhibitors.

Publication types

Editorial
Comment